Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Camrelizumab

Generic Name: Camrelizumab

Drug Type: Biotech

CAS Number: 1798286-48-2

Unique Ingredient Identifier: 73096E137E

Overview

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Background

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication

⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。 ⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。 ⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。 ⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Phase 3

Recruiting

Posted: 2021/09/14

Sponsor:

Zhigang Li

ID:NCT05043688

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3

Recruiting

Posted: 2021/09/13

Sponsor:Jiangsu HengRui Medi...

ID:NCT05042375

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Phase 1

Posted: 2021/08/25

Sponsor:West China Hospital

ID:NCT05019534

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Phase 2

Recruiting

Posted: 2021/08/18

Sponsor:Eye & ENT Hospital o...

ID:NCT05011227

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

Phase 2

Posted: 2021/08/13

Sponsor:Shanghai Chest Hospi...

ID:NCT05005468

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

HAIC with FOLFOX Plus Camrelizumab and Sorafenib Shows Limited Efficacy in Advanced HCC

14 days ago

A phase II trial investigating hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib in BCLC stage C hepatocellular carcinoma failed to meet its primary endpoint, showing a modest 44% objective response rate.

Neoadjuvant Immunochemotherapy Shows Promising Results in Locally Advanced Oral Squamous Cell Carcinoma

25 days ago

Neoadjuvant immunochemotherapy with camrelizumab plus nab-paclitaxel and cisplatin demonstrated a favorable pathological response in patients with locally advanced oral squamous cell carcinoma, achieving a 69% major pathological response rate and 41.4% pathological complete response rate.

Innovative Trial Designs Emerge After Immunotherapy Setbacks in Head and Neck Cancer

2 months ago

Recent phase 3 trials KEYNOTE-412 and JAVELIN Head and Neck 100 failed to show survival benefits when adding immunotherapy to chemoradiotherapy in locally advanced head and neck cancer, prompting researchers to investigate alternative treatment sequences.

FDA Issues Second Rejection for Rivoceranib/Camrelizumab Combination in Unresectable Liver Cancer

2 months ago

The FDA has issued a second Complete Response Letter (CRL) for the rivoceranib/camrelizumab combination therapy for unresectable hepatocellular carcinoma, with no specific reasons disclosed for the rejection.

HLB Group to Resubmit Riboceranib for FDA Approval Following Second Rejection

2 months ago

HLB Group announced plans to resubmit its targeted anticancer drug riboceranib for FDA approval by May after receiving a second rejection due to manufacturing issues with partner Hangseo Pharmaceutical.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy